Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/Sales ratio high or low?
The EV/Sales ratio of 91.23x is 24% below its estimated 1-year average of 120.79x, near the low end of its estimated 1-year range (91.23x–141.66x).
As of 2026-10-06T12:05:24.747Z.
Calculation as of: 2026-10-06T12:05:24.747Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6ac0f7718e38414e938d0d293bbdd3741326646c7ebae4135e2c8e12d98e3a9c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
91.23x
EV/SALES RATIO AVG TTM
N/A
EV/SALES RATIO AVG 3Y
N/A
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.22x
median of 262 covered companies
CURRENT VS SECTOR MEDIAN
+2059.29%
vs the sector median at left
Market Cap
$985.79M
EV/Sales Ratio
N/A
TTM Avg
38.08x
3Y Avg
38.08x
5Y Avg
38.08x
Market Cap
$1.05B
EV/Sales Ratio
0.53x
TTM Avg
0.60x
3Y Avg
0.81x
5Y Avg
2.06x
Market Cap
$922.50M
EV/Sales Ratio
4.99x
TTM Avg
36.22x
3Y Avg
50.65x
5Y Avg
36.89x
Market Cap
$903.13M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$867.60M
EV/Sales Ratio
28.39x
TTM Avg
18.85x
3Y Avg
39.02x
5Y Avg
39.02x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aktis Oncology, Inc. (AKTS) | $989.05M | 91.23x | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | N/A | 38.08x | 38.08x | 38.08x |
| CeriBell, Inc. (CBLL)vs › | $943.26M | 9.15x | 7.82x | 8.63x | 8.63x |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 0.53x | 0.60x | 0.81x | 2.06x |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | 4.99x | 36.22x | 50.65x | 36.89x |
| Bioventus Inc. (BVS)vs › | $915.95M | 1.98x | 1.63x | 1.56x | 1.52x |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | 28.39x | 18.85x | 39.02x | 39.02x |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 2.17x | 2.15x | 3.23x | 3.44x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2026-10-05 | 94.76x |
| 2026-10-02 | 94.76x |
| 2026-10-01 | 94.76x |
| 2026-09-30 | 99.98x |
| 2026-09-29 | 101.19x |
| 2026-09-28 | 99.32x |
| 2026-09-25 | 99.76x |
| 2026-09-24 | 100.86x |
| 2026-09-23 | 101.36x |
| 2026-09-22 | 114.50x |
| 2026-09-21 | 110.76x |
| 2026-09-18 | 113.23x |
| 2026-09-17 | 118.62x |
| 2026-09-16 | 117.80x |
| 2026-09-15 | 116.15x |
| 2026-09-14 | 120.33x |
| 2026-09-11 | 121.04x |
| 2026-09-10 | 124.56x |
| 2026-09-09 | 125.22x |
| 2026-09-08 | 130.50x |
| 2026-09-04 | 141.66x |
| 2026-09-03 | 139.46x |
| 2026-09-02 | 140.95x |
| 2026-09-01 | 135.83x |
| 2026-08-31 | 135.39x |
| 2026-08-28 | 134.68x |
| 2026-08-27 | 136.88x |
| 2026-08-26 | 138.69x |
| 2026-08-25 | 139.68x |
| 2026-08-24 | 135.78x |
| 2026-08-21 | 125.28x |
| 2026-08-20 | 124.89x |
| 2026-08-19 | 130.50x |
| 2026-08-18 | 130.39x |
| 2026-08-17 | 128.85x |
| 2026-08-14 | 130.01x |
